Dynamic Relevance Between Reflux Events and Esophageal Motility in Patients With Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease

Abstract

Objectives: The association between reflux events and esophageal motility abnormality is unclear. We aimed to determine the relevance between reflux events and esophageal motility in proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD).

Methods: Patients with PPI-refractory or PPI-responsive GERD were enrolled. Ambulatory 24-h esophageal pH–impedance–pressure monitoring was performed. Reflux symptoms, reflux events, and esophageal motility during acid reflux episodes were recorded and compared between the two groups.

Results: Sixty patients with PPI-refractory GERD and 18 with PPI-responsive GERD were included, all of whom had pathological gastroesophageal reflux. There were no significant differences in the major acid reflux parameters (DeMeester score and proportion of patients with acid exposure time > 6%) between the two groups. However, the number of long acid reflux episodes and the time length of the longest reflux episodes were significantly higher in the PPI-refractory GERD group than in the PPI-responsive GERD group (both p < 0.05). Moreover, patients with PPI-refractory GERD had higher rates of ineffective primary (62.0% vs. 36.0%, p < 0.001) and secondary peristalsis (83.5% vs. 57.0%, p = 0.001) during long acid exposure (LAE) than those with PPI-responsive GERD. Patients with PPI-refractory GERD having LAE had a significantly lower frequency of primary and secondary peristalsis per minute and required a longer time to initiate secondary peristalsis than those without during their longest acid reflux period in the upright position (all p < 0.001).

Conclusion: Longer acid reflux episodes in patients with PPI-refractory GERD might result from frequent ineffective primary esophageal peristalsis and delayed initiation of effective secondary peristalsis.

Keywords

acid reflux / esophageal motility disorders / esophageal pH monitoring / gastroesophageal reflux

References

[1] K. B. Dunbar, “Gastroesophageal Reflux Disease,” Annals of Internal Medicine 177, no. 8 (2024): ITC113-ITC128.

[2] K. M. Fock, N. Talley, K. L. Goh, et al., “Asia-Pacific Consensus on the Management of Gastro-Oesophageal Reflux Disease: An Update Focusing on Refractory Reflux Disease and Barrett's Oesophagus,” Gut 65, no. 9 (2016): 1402-1415.

[3] M. Desjardin, G. Luc, D. Collet, and F. Zerbib, “24-Hour pH-Impedance Monitoring on Therapy to Select Patients With Refractory Reflux Symptoms for Antireflux Surgery. A Single Center Retrospective Study,” Neurogastroenterology and Motility 28, no. 1 (2016): 146-152.

[4] P. O. Katz, L. B. Gerson, and M. F. Vela, “Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease,” American Journal of Gastroenterology 108, no. 3 (2013): 308-328.

[5] R. Yadlapati, C. P. Gyawali, and J. E. Pandolfino, “AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review,” Clinical Gastroenterology and Hepatology 20, no. 5 (2022): 984-994.e1.

[6] R. Fass, G. E. Boeckxstaens, H. El-Serag, R. Rosen, D. Sifrim, and M. F. Vaezi, “Gastro-Oesophageal Reflux Disease,” Nature Reviews Disease Primers 7, no. 1 (2021): 55, https://doi.org/10.1038/s41572-021-00287-w.

[7] Y. L. Xiao, J. C. Y. Wu, C.-L. Lu, et al., “Clinical Practice Guidelines for Esophageal Ambulatory Reflux Monitoring in Chinese Adults,” Journal of Gastroenterology and Hepatology 37, no. 5 (2022): 812-822.

[8] J. Abdallah, N. George, T. Yamasaki, S. Ganocy, and R. Fass, “Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders,” Clinical Gastroenterology and Hepatology 17, no. 6 (2019): 1073-1080.e1.

[9] R. Yadlapati, P. J. Kahrilas, M. R. Fox, et al., “Esophageal Motility Disorders on High-Resolution Manometry: Chicago Classification Version 4.0^©,” Neurogastroenterology and Motility 33, no. 1 (2021): e14058, https://doi.org/10.1111/nmo.14058.

[10] S. Jandee, S. Keeratichananont, J. Tack, and T. Vanuytsel, “Concise Review: Applicability of High-resolution Manometry in Gastroesophageal Reflux Disease,” Journal of Neurogastroenterology and Motility 28, no. 4 (2022): 531-539.

[11] L. Q. Jiang, B. X. Ye, Y. Wang, M. F. Wang, and L. Lin, “Esophageal Body Motility for Clinical Assessment in Patients with Refractory Gastroesophageal Reflux Symptoms,” Journal of Neurogastroenterology and Motility 23, no. 1 (2017): 64-71.

[12] X. Q. Li, S. H. Lin, Z. F. Wang, et al., “Gastroesophageal Reflux Disease and Chronic Cough: A Possible Mechanism Elucidated by Ambulatory pH-Impedance-Pressure Monitoring,” Neurogastroenterology and Motility 31, no. 12 (2019): e13707, https://doi.org/10.1111/nmo.13707.

[13] Y. Chan, J. Y. L. Ching, C. M. Y. Cheung, et al., “Development and Validation of a Disease-Specific Quality of Life Questionnaire for Gastro-Oesophageal Reflux Disease: The GERD-QOL Questionnaire,” Alimentary Pharmacology and Therapeutics 31, no. 3 (2010): 452-460.

[14] S. Vigneri, R. Termini, G. Leandro, et al., “A Comparison of Five Maintenance Therapies for Reflux Esophagitis,” New England Journal of Medicine 333, no. 17 (1995): 1106-1110.

[15] J. K. DiBaise, “The LA Classification for Esophagitis: A Call for Standardization,” American Journal of Gastroenterology 94, no. 12 (1999): 3403-3404.

[16] A. L. Vaccarino, K. R. Evans, T. L. Sills, and A. H. Kalali, “Symptoms of Anxiety in Depression: Assessment of Item Performance of the Hamilton Anxiety Rating Scale in Patients With Depression,” Depression and Anxiety 25, no. 12 (2008): 1006-1013.

[17] T. V. K. Herregods, A. Pauwels, J. Jafari, et al., “Ambulatory pH-Impedance-Pressure Monitoring as a Diagnostic Tool for the Reflux-Cough Syndrome,” Diseases of the Esophagus 31, no. 1 (2018): 1-7.

[18] M. Ghisa, B. Barberio, V. Savarino, et al., “The Lyon Consensus: Does It Differ From the Previous Ones?,” Journal of Neurogastroenterology and Motility 26, no. 3 (2020): 311-321.

[19] E. Chrysos, E. Athanasakis, O. J. Zoras, J. Tsiaoussis, and E. Xynos, “Twenty-Four-Hour Ambulatory Versus Stationary Esophageal Manometry in the Evaluation of Esophageal Motility in Patients With Gastroesophageal Reflux Disease,” Digestion 66, no. 1 (2002): 1-8.

[20] C. Wang and R. H. Hunt, “Precise Role of Acid in Non-Erosive Reflux Disease,” Digestion 78, no. Suppl 1 (2008): 31-41.

[21] L. Q. Jiang, B. X. Ye, M. F. Wang, and L. Lin, “Acid Exposure in Patients With Gastroesophageal Reflux Disease Is Associated With Esophageal Dysmotility,” Journal of Digestive Diseases 20, no. 2 (2019): 73-77.

[22] R. R. Chen, Q. Z. Chen, B. C. Feng, et al., “Characteristics of Reflux and Gastric Electrical Activity in Gastroesophageal Reflux Disease With Ineffective Esophageal Motility,” Journal of Digestive Diseases 24, no. 1 (2023): 2-9.

[23] K. Hwang, “Mechanism of Transportation of the Content of the Esophagus,” Journal of Applied Physiology 6, no. 12 (1954): 781-796.

[24] M. W. Wong, C. H. Yi, T. T. Liu, et al., “Effects of Phosphodiesterase-5 Inhibitor Sildenafil on Esophageal Secondary Peristalsis: Studies With High-Resolution Manometry,” Journal of Gastroenterology and Hepatology 36, no. 2 (2021): 430-435.

[25] K. Iwakiri, Y. Hayashi, M. Kotoyori, et al., “Defective Triggering of Secondary Peristalsis in Patients With Non-Erosive Reflux Disease,” Journal of Gastroenterology and Hepatology 22, no. 12 (2007): 2208-2211.

[26] C. G. Aben-Athar and R. O. Dantas, “Primary and Secondary Esophageal Contractions in Patients With Gastroesophageal Reflux Disease,” Brazilian Journal of Medical and Biological Research 39, no. 8 (2006): 1027-1031.

[27] J. Kravitz, J. Snape,, and S. Cohen, “Effect of Thoracic Vagotomy and Vagal Stimulation on Esophageal Function,” American Journal of Physiology 234, no. 4 (1978): E359-E364.

[28] I. M. Lang, B. K. Medda, and R. Shaker, “Mechanisms of Reflexes Induced by Esophageal Distension,” American Journal of Physiology Gastrointestinal and Liver Physiology 281, no. 5 (2001): G1246-G1263.

[29] C. L. Chen, C. H. Yi, and T. T. Liu, “Relevance of Ineffective Esophageal Motility to Secondary Peristalsis in Patients With Gastroesophageal Reflux Disease,” Journal of Gastroenterology and Hepatology 29, no. 2 (2014): 296-300.

[30] W. Y. Lei, T. T. Liu, J. H. Wang, et al., “Impact of Ineffective Esophageal Motility on Secondary Peristalsis: Studies With High-Resolution Manometry,” Neurogastroenterology and Motility 33, no. 4 (2020): e14024, https://doi.org/10.1111/nmo.14024.

[31] A. Anggiansah, G. Taylor, N. Bright, et al., “Primary Peristalsis Is the Major Acid Clearance Mechanism in Reflux Patients,” Gut 35, no. 11 (1994): 1536-1542.

[32] R. H. Holloway, “Esophageal Body Motor Response to Reflux Events: Secondary Peristalsis,” American Journal of Medicine 108, no. Suppl 4a (2000): 20S-26S.

[33] B. F. Kessing, A. J. P. M. Smout, R. J. Bennink, N. Kraaijpoel, J. M. Oors, and A. J. Bredenoord, “Prucalopride Decreases Esophageal Acid Exposure and Accelerates Gastric Emptying in Healthy Subjects,” Neurogastroenterology and Motility 26, no. 8 (2014): 1079-1086.

[34] C.-H. Yi, W.-Y. Lei, J.-S. Hung, T.-T. Liu, and C.-L. Chen, “Effects of Prucalopride on Esophageal Secondary Peristalsis in Humans,” Clinical and Translational Gastroenterology 7, no. 11 (2016): e202, https://doi.org/10.1038/ctg.2016.58.

RIGHTS & PERMISSIONS

2025 The Author(s). Journal of Digestive Diseases published by Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.